Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

Mass General Brigham

Status: Unknown

Conditions: Atrial Fibrillation; Stroke; Anticoagulant-induced Bleeding; Frailty

Treatments: Drug: Dabigatran; Drug: Warfarin; Drug: Edoxaban; Drug: Apixaban; Drug: Rivaroxaban

Study type: Observational

Funder types: Other

Identifiers

NCT04878497

2019P000110-NOAC

Details and patient eligibility

About

The objective of this study is to establish a near-real-time prospective monitoring program in Medicare, Optum and MarketScan Research data to evaluate the benefit of new cardiovascular disease (CVD) drugs for older adults with frailty. Prospective monitoring program seeks to find early effectiveness and safety signals of new drugs by updating the analysis at regular intervals as new Medicare data become available. This study specifically aims to emulate a prospective surveillance of the effectiveness and safety of non-vitamin K oral anticoagulants (NOAC) vs. a comparator, warfarin, in older adults with atrial fibrillation and different frailty status. This program will be enhanced by incorporating a novel claims-based frailty index, which has been shown useful in assessing how the benefits and harms of drug therapy vary by frailty.

Full description

Data sources of use for this study are: Medicare Database, Optum Database, and MarketScan Research Database. All data from years 2013-2020 (available data may vary depending on the database) will be analyzed in the study.

This study follows a sequential cohort monitoring design. The monitoring analysis will include 1) retrospective analysis of available data (2013-2018) at the time of first analysis (April 2021) and 2) prospective analysis of new data (2019-2020) as they become available to the researchers. Within each database and by frailty status (frail vs non-frail), the investigators will emulate annual updating of data by creating a propensity score (PS)-matched cohort of new users every 1-year interval. Each sequential cohort will be followed for development of the outcomes of interest. At the end of each interval, time-to-event data from all sequential cohorts will be pooled for outcome analysis. The surveillance will be performed by frailty status (frail vs non-frail) at the time of drug initiation.

Enrollment: 1,000,000 estimated patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Initiation of a NOAC or warfarin (day 0 is the initiation day)
• Continuous enrollment in medical and drug insurance in [-183, 0] days
• Diagnosis of AF in [-183, 0] days
• CHA2DS2-VASc score ≥2 (moderate or high risk for stroke)
• No prior use of NOAC or warfarin in [-183, -1] days
• No recent hospitalization for stroke or major bleeding in [-60, 0] days
• No recent nursing facility stay in [-60, 0] days

Exclusion criteria

• Contraindication to either drug in [-183, 0] days
• Valvular heart disease or mechanical heart valve in [-183, 0] days
• Intracranial or retroperitoneal hemorrhage in [-183, 0] days
• Chronic kidney disease stage V, end-stage renal disease, or dialysis in [-183, 0] days
• Other indications for anticoagulation therapy in [-183, 0] days

Trial design

1,000,000 participants in 5 patient groups

Warfarin

Description:

New users of warfarin

Treatment:

Drug: Warfarin

Dabigatran

Description:

New users of dabigatran

Treatment:

Drug: Dabigatran

Rivaroxaban

Description:

New users of rivaroxaban

Treatment:

Drug: Rivaroxaban

Apixaban

Description:

New users of apixaban

Treatment:

Drug: Apixaban

Edoxaban

Description:

New users of edoxaban

Treatment:

Drug: Edoxaban